AC Immune SA, a clinical-stage biopharmaceutical company, is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications. We are addressing the social and economic imperative created by the growing incidence of neurodegenerative diseases.
Our deep knowledge and cutting-edge technology platforms are the engines for our diverse pipeline of clinical and preclinical product candidates including vaccines, antibodies, small molecule drugs and diagnostic agents. We have pioneered scientific and clinical advances in the understanding and treatment of neurodegeneration.
Our scientific leadership, technologies and pipeline have been validated by our partnerships with global pharmaceutical leaders: Genentech, a member of the Roche group, Janssen Pharmaceuticals, and Eli Lilly and Co.
